SafeGuard Surgical

Executive Summary

SafeGuard Surgical is a private, US-based medical device company founded in 2019 and headquartered in Aliso Viejo, California. The company specializes in developing innovative, biodegradable surgical devices aimed at enhancing safety and precision, initially targeting ophthalmic procedures with a broader surgical platform. Its lead product, LeakGuard™, has received FDA Breakthrough Device designation for preventing surgical leaks, which could significantly reduce complications, mortality, and healthcare costs. The technology addresses a critical unmet need in surgery, where fluid leaks often lead to severe outcomes. SafeGuard Surgical is still in early stages, with no disclosed funding rounds or revenue, but the Breakthrough Device status positions it for expedited regulatory review and potential market entry.

Upcoming Catalysts (preview)

• Q4 2026FDA Premarket Approval or 510(k) Submission for LeakGuard40% success
• Q3 2026Series A Funding Round Closing60% success
• Q1 2027Initial Clinical Trial Results for LeakGuard50% success